Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Roth Capital analyst Jonathan Aschoff initiates coverage on NeOnc Technologies Hldgs (NASDAQ:NTHI) with a Buy rating and announces Price Target of $20.
NeOnc Technologies (NASDAQ: NTHI) is advancing NEO100, an intranasal-delivered therapy for IDH1-mutant gliomas, following promising Phase 2a results showing 48.9% six-month progression-free survival versus a 20% benchmark with no major toxicities. The company plans to seek FDA guidance on a registrational pathway, with potential broader implications for nose-to-brain drug delivery technology.
Filed: 2026-09-21 AccNo: 0001829126-26-010282 Size: 227 KB Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
NeOnc Technologies (NASDAQ: NTHI) reported Phase 2a results for NEO100, an intranasal formulation of perillyl alcohol for recurrent high-grade glioma. The 24-patient study showed 48.9% six-month progression-free survival versus a 20% benchmark (p=0.0047), with median overall survival of 26.09 months. The novel nose-to-brain delivery approach aims to overcome blood-brain barrier challenges. While results are encouraging, the small sample size and open-label design warrant confirmation in larger randomized trials before regulatory approval.